Search tips
Search criteria 


Logo of neurotherwww.springer.comThis journalToc AlertsSubmit OnlineOpen Choice
Neurotherapeutics. 2017 July; 14(3): 830.
Published online 2017 March 10. doi:  10.1007/s13311-017-0517-z
PMCID: PMC5509622

Erratum to: Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial

Erratum to: Neurotherapeutics

DOI 10.1007/s13311-016-0508-5

The phrase “and family members” should be deleted from the second sentence in Paragraph 1 of Discussion. The correct sentence is:

“Considering past ALS treatment trials, this study is unique for several reasons. Firstly, it was driven by reports from patients who, having been treated for one condition (PBA), reported unexpected benefit upon seemingly unrelated symptoms.”

The sentence starting on line 11, Paragraph 2 of Discussion should read:

Just under half (49%) of the subjects in this study improved by one or more points in the ALSFRS-R bulbar domain with DMQ treatment relative to their response on placebo (26%).


The online version of the original article can be found at

Articles from Neurotherapeutics are provided here courtesy of Springer